|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Strategies and Solutions for Publication Planning and Execution Excellence
|
Sep 2007 |
£75 |
100% |
Cystoid Macular Edema Global Clinical Trials Review
H2 2011
|
Nov 2011 |
£630 |
98% |
|
Terumo Corporation Product Pipeline Analysis
|
Jan 2009 |
£475 |
95% |
|
BSD Medical Corporation Product Pipeline Analysis
|
Jan 2009 |
£475 |
92% |
Healthcare and Pharmaceuticals in Latin America
A guide to the markets and regulations
|
Sep 2011 |
£995 |
92% |
|
State of the Clinical Trials Industry 2007
|
May 2007 |
£380 |
92% |
Intercell AG – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
91% |
Good Clinical Practice
A Question & Answer Reference Guide 2010
|
May 2010 |
£29 |
90% |
Wounds - Pipeline Review
H2 2011
|
Aug 2011 |
£315 |
87% |
Stakeholder Opinion: Erectile Dysfunction
Identifying product differentiation and patient segmentation strategies
|
Dec 2006 |
£2,400 |
85% |
|
Gene Therapy
|
Jan 2011 |
£2,845 |
85% |
|
Reporting Adverse Events
|
Sep 2006 |
£75 |
84% |
Genfit – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
84% |
Clinical Trials: World Market
2010-2025
|
Jul 2010 |
£1,499 |
84% |
RNAi for Therapeutic Applications
Market Prospects 2011-2021
|
Mar 2011 |
£1,499 |
84% |
Pharma Clinical Trial Services
World Market 2011-2021
|
Jul 2011 |
£1,499 |
83% |
|
Bausch & Lomb Incorporated Product Pipeline Analysis
|
Jan 2009 |
£475 |
83% |
|
ASCO 2009: Significant Developments in Context
|
Jul 2009 |
£595 |
82% |
|
The Executive Guide to Molecular Imaging
|
Jul 2007 |
£595 |
81% |
Stakeholder Opinions: Tropical Diseases
Dengue, Japanese encephalitis and West Nile virus – Increasing attention for neglected diseases
|
Dec 2010 |
£2,405 |
79% |
|
Glossary & Acronyms for Clinical Research Professionals
|
Feb 2009 |
£13 |
79% |
Novabiotics Ltd - Product Pipeline Review
Q4 2010
|
Dec 2010 |
£315 |
78% |
4SC AG – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
78% |
Radiopharmaceuticals
A US and European Market Analysis
|
Nov 2009 |
£1,895 |
78% |
|
Germany Diagnostic Imaging Investment Opportunities, Analysis and Forecasts to 2012
|
Feb 2009 |
£1,895 |
78% |
|
Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
|
Sep 2008 |
£8,365 |
77% |
Cubist Pharmaceuticals, Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
76% |
|
All Change in the Coronary Stent Market
|
May 2010 |
£695 |
76% |
|
Marine Biotechnology
|
Jan 2011 |
£2,845 |
76% |
|
Medical Weekly Deals Summaries 29 June 2009
|
Jun 2009 |
£79 |
76% |
